The funds will support the advancement and evaluation of candidates in phase I clinical trials.

Phage-based vaccine platforms can quickly adjust the vaccine in response to mutations in the coronavirus, are self-adjuvanted (activate and boost immune responses), and have the ability to display multiple antigens. The company is exploring the potential for an oral delivery system in the form of a lozenge for the vaccine and booster doses.

The company anticipates that phase I trials will demonstrate the safety and immunogenicity of the phage-based vaccine. If the phase I trials are successful, the company will plan to advance the vaccine through phase III studies and regulatory approval.

Therapure to manufacture VBI coronavirus vaccines
Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.

Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...

IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.